Disease Monitoring In Multiple Myeloma

被引：1
|
作者：
Hillengass, Jens [1 ]
Martin, Tom [2 ]
Puig, Noemi [3 ]
Paiva, Bruno [4 ]
Usmani, Saad [5 ]
Kumar, Shaji [6 ]
San-Miguel, Jesus [4 ,7 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Dept Hematol Salamanca, Salamanca, Spain
[4] Clin Univ Navarra, CCUN, CIMA, CIBERONC,IDISNA, Pamplona, Spain
[5] Levine Canc Inst Atrium Hlth, Charlotte, NC USA
[6] Mayo Clin, Dept Hematol, Rochester, MN USA
[7] Clin Univ Navarra, Pio 12 Ave 36, Pamplona 31008, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷 / 04期
关键词：
POSITRON-EMISSION-TOMOGRAPHY; MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; IMAGING TECHNIQUES; COMPLETE RESPONSE; SURVIVAL; DIAGNOSIS; THERAPY; CORRELATE; PATTERNS;
D O I：
10.1016/j.clml.2023.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：244 / 248
页数：5
相关论文
共 50 条
  • [1] Minimal residual disease in multiple myeloma: Benefits of flow cytometry
    Galtseva, I. V.
    Davydova, Y. O.
    Kapranov, N. M.
    Julhakyan, H. L.
    Mendeleeva, L. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : 12 - 20
  • [2] Advances in minimal residual disease monitoring in multiple myeloma
    Wijnands, Charissa
    Noori, Somayya
    van de Donk, Niels W. C. J.
    VanDuijn, Martijn M.
    Jacobs, Joannes F. M.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
  • [3] Multiple myeloma: disease response assessment
    Zamagni, E.
    Tacchetti, P.
    Terragna, C.
    Cavo, M.
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (09) : 831 - 837
  • [4] Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma
    Kim, Susanna
    Berenson, James R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (09) : 484 - 493
  • [5] Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
    Korthals, Mark
    Sehnke, Nina
    Kronenwett, Ralf
    Schroeder, Thomas
    Strapatsas, Tobias
    Kobbe, Guido
    Haas, Rainer
    Fenk, Roland
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (07) : 1109 - 1115
  • [6] Response evaluation and monitoring of multiple myeloma
    Fernandez de Larrea, Carlos
    Delforge, Michel
    Davies, Faith
    Blade, Joan
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 33 - 42
  • [7] Minimal residual disease monitoring in multiple myeloma
    Davies, FE
    Rawstron, RC
    Owen, RG
    Morgan, GJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
  • [8] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [9] Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
    Diamond, Benjamin T.
    Rustad, Even
    Maclachlan, Kylee
    Thoren, Katie
    Ho, Caleb
    Roshal, Mikhail
    Ulaner, Gary A.
    Landgren, C. Ola
    BLOOD REVIEWS, 2021, 46
  • [10] Heavy plus light chain monitoring correlates with clinical outcome in multiple myeloma patients
    Michallet, M.
    Chapuis-Cellier, C.
    Dejoie, T.
    Lombard, C.
    Caillon, H.
    Sobh, M.
    Moreau, P.
    Attal, M.
    Avet-Loiseau, H.
    LEUKEMIA, 2018, 32 (02) : 376 - 382
12345